The abbreviation "RR" generally refers to relative risk, and should thus be interpreted as a ratio of two estimates of risk in epidemiological studies, be it a ratio of odds (odds ratio), risks (risk ratio), rates (rate ratio), or hazards (hazard ratio). Knowing which type of comparison is being made is essential for interpretation. As such, the specific effect size measure used should always be explicitly mentioned. Regardless of type, the relative risk has multiple practical applications in clinical research, as it not only provides an answer to the question "is there an association?" but also "how large is the association?", thereby supplying information about the magnitude and direction of the effect (e.g, harmful or protective). This is because the relative risk is calculated by dividing the risk of the outcome in the group with the exposure of interest by the risk of the outcome observed in the unexposed group. However, as with all ratio measurements, the absolute size of the numerator and denominator are lost 1 (see Box 1). This loss of information impedes interpretation, as it becomes difficult to understand the true impact of exposure. In this paper, we suggest multiple ways you, as both an author and critical reader of scientific publications, can put relative risks into meaningful context. In order to do so, we first need to establish a typology of domains in which relative risks are being used. 
Generally speaking, all clinical research can be divided into four categories using typical questions a patient might ask a doctor when 
| QUANTIFYING THE IMPACT
In both intervention and etiologic research domains, it is pivotal to isolate the effect of interest from other factors by selecting a suitable study design and sample, identifying and measuring potential confounding factors, as well as choosing appropriate statistical methods. In clinical trials, this means using tools such as randomization and concealment of treatment allocation to minimize bias and isolate the treatment effect. In observational studies, confounding control is needed to single out the effect of a causal factor using strategies such as stratification or regression adjustment. Recently, more advanced methods such as propensity score matching and inverse probability of treatment weighting have been popularized. Ultimately, it is often the relative risk that provides insight into the strength of an effect, be it a treatment effect or an estimate of the causal effect of a particular risk factor. However, as the ratio of two risk measures omits critical information about the absolute risk, one cannot easily judge the external validity of a study nor understand the contribution of a single factor to the total risk with this metric alone.
| ABSOLUTE RISK
The internal validity of a study refers to the extent to which the study minimizes potential biases, which could render the results invalid. In contrast, and perhaps more interesting in this context, external validity of a study refers to the extent to which the individual study results can be generalized to other populations. To make this assessment, a thorough understanding of the study population characteristics, customarily presented in Table 1 of scientific articles, is important. Next to this, the overall absolute risk of the outcome of interest plays an integral role in the external validity of a study. For example, meaningful differences in absolute risks between the study population and another population could indicate a difference in the prevalence of comorbidities or a difference in how healthcare is organized. This can have effects on both absolute and relative risk measures; when the absolute risk in a population is high, or the exposure is highly prevalent, relative risk estimates are generally smaller. Therefore, without knowing information about the absolute risk and the prevalence of the exposure, it is difficult to determine whether the generalization of results from one population to another is appropriate.
| "NUMBER NEEDED TO"
Some of the information needed to assess the contribution of a single factor to the total risk in interventional studies is provided by the risk difference (RD), a useful absolute measure that allows for ready calculation of the number needed the treat (NNT). Computed by taking the inverse of the absolute risk difference, the NNT provides an idea of efficacy (or effectiveness) by providing an answer to the question, "How many patients do we need to treat in order to prevent the occurrence of a single event?" The usefulness of the NNT in the context of a randomized controlled trial is particularly convenient, since the NNT can be easily calculated from the crude, unadjusted analyses in well-conducted trials. On the other hand, in observational research, we should not simply calculate NNT from crude data due to bias and confounding. Certain regression-based approaches such Poisson and Cox proportional hazards regression are capable of controlling for confounding and thus come to a more valid estimate NNT.
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The NNT concept can also be extended to apply to harmful ex- First, we will use the table to calculate the risk among young women exposed and not exposed to X and compare these risks using a risk ratio.
| POPULATION ATTRIBUTABLE FRACTION

Risk of disease D (cumulative incidence):
Among the exposed 50/1000 = 0.05
Among the unexposed 25/3000 = 0.0083
Risk ratio (type of relative risk, RR): Both measures on the absolute scale are not very high. The low absolute risk and the risk difference put the 6-fold increase in risk in some perspective. But how can we make these numbers even more understandable in a clinically relevant context? We can calculate the number needed to harm, which tells us how many young women on average would need to be exposed to X for one additional woman to develop disease D.
Number needed to harm (NNH): This means that, on average, for every 24 young women exposed to X, 1 will develop disease D (24 "need to be exposed" for 1 to be "harmed").
Since we know diseases are multicausal, it may be useful to know what proportion of all cases of disease in our study population can be attributed to exposure X. To do this, we first need to calculate two pieces of information:
1. The proportion of exposed cases of disease:
Proportion exposed cases Number of exposed participants with disease/Total participants with disease 50/75 = 0.667 (=67%)
The attributable fraction among the exposed (AF):
AF RD/Risk among the exposed 0.042/0.05 = 0.84 (=84%)
Now, we simply multiply these two numbers together to get the population attributable fraction (PAF) as follows.
Population attributable fraction (PAF):
PAF Proportion of exposed cases × Attributable fraction among exposed 0.667 × 0.840 = 0.56 (=56%)
This example illustrates three valuable lessons: First, it shows that in order to interpret a high relative risk, additional context is needed.
When the absolute risk for a particular disease is low, a high relative risk is less concerning. The risk difference is therefore often more intuitive and can readily interpreted as "excess risk". Second, calculating the NNH (or a related measure) provides further useful information that can aid in decision making. In the case of NNH, lower numbers are more concerning Third, the PAF answers a different contextual question; specifically, what fraction of all cases can be attributed to the exposure? Taking the prevalence of the exposure in the population into account, the PAF tells us that more than half of the total cases of disease D could be attributed to exposure X.
PAF. 6 For this reason, the PAF is considered an appropriate tool to evaluate the impact of individual risk factors on a population level.
Importantly, the PAF is dependent not only on the strength of the effect of the exposure on the outcome, but also on the absolute risk of outcome as well as the prevalence of the exposure in the population; two additional valuable pieces of contextual information (see Box 2) . For these reasons, PAFs calculated using data from well-conducted cohort and case-control studies provide meaningful information beyond the relative risk. When calculating and reporting PAFs, two major issues must be considered: as PAFs are often obtained from observational data, the PAFs are dependent on the extent of bias in the data. Additionally, many thrombotic diseases are multicausal, meaning there are (theoretically) multiple ways to prevent the onset of a single event. 7 Therefore, it follows that the sum of PAFs for all risk factors is not capped at 1; in fact, the sum of all PAFs for a particular outcome often exceeds this number.
| BEYOND THE BINARY OUTCOME
To understand the impact of a treatment or biomarker, it can be useful to look beyond a dichotomous outcome and instead make use of a clinically relevant measurement with multiple levels. Many research fields regularly use such approaches to assess outcomes with multiple levels, especially when they are ordinal in nature (e.g, outcomes after birth, pain management, rheumatology and surgery). [8] [9] [10] [11] This approach is distinct from the practice of using so-called "surrogate outcomes", in which binary outcomes are also replaced, for example, by a biomarker. 12 This practice is debated, primarily as the clinical relevance is often unclear. If one wants to create or adopt ordinal outcomes that are not surrogate outcomes, the clinical relevance of the outcome categories needs to be a guiding principle.
A well-known example from stroke research is the modified Rankin Scale (mRS), which has seven ordered steps of patient functionality, ranging from "no impairment" (mRS = 0) to "dead" (mRS = 6)
Box 2 Multiple measures paint the full picture
For a complete understanding of the impact of your results, it is important to consider multiple measures as discussed in this paper.
Below, we provide six different variations on the cohort study studying the effect of exposure X on disease D in 4000 young women, as and is traditionally measured three months after the initial stroke. 13 The scale is interview-based, and as such, is not as objective as some binary outcomes. However, the scale has a good inter-observer agree- 
| SUMMARY
Relative risk estimates provide an answer to the research question at hand; however, due to their relative nature, they do not convey the necessary context for meaningful interpretation. Ultimately, it is the duty of the authors of a publication to go beyond the relative risk and explicitly provide the context needed to help readers un- 
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